Search Results

You are looking at 121 - 130 of 868 items for :

  • Refine by Access: All x
Clear All
Full access

Systemic Therapy for Small Cell Lung Cancer

Benjamin Levy, Ashish Saxena, and Bryan J. Schneider

inevitably experience disease relapse and die. Unfortunately, scientific research has yielded few advances over the past 30 years, resulting in a dismal median survival time for ES-SCLC of 8 to 10 months. However, renewed interest has been shown in

Full access

Optimizing Endocrine Therapy for Breast Cancer

Amelia B. Zelnak and Ruth M. O'Regan

improved outcomes for patients with all stages of hormone receptor (HR)–positive breast cancer. However, despite the marked success of endocrine therapy in the treatment of HR-positive breast cancers, many patients will experience relapse and all patients

Full access

Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

investigators pooled estimates for distant metastases, visceral recurrences, and occurrence rate of locoregional relapses. Considering that treatment outcomes may vary among different types of bisphosphonates, the investigators performed subgroup analyses for

Full access

Thymoma Complicated by Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia

Carl M. Gay, William N. William Jr, Sa A. Wang, and Thein Hlaing Oo

discontinued in September 2011. Two months later, his Hb level and platelet count decreased again. Bone marrow biopsy showed relapsed PRCA and AAMT. He was then restarted on cyclosporine, 300 mg/d, and his Hb level and platelet count subsequently increased

Full access

Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature

Ivan Lolli, Anna Maria Valentini, Angela Dalia Ricci, and Raffaele Armentano

aggressiveness led to transfemoral amputation of the left leg and a lung metastasectomy. Further amputation at a higher level was proposed at the subsequent relapse at the left stump level. The choice of immunotherapy with pembrolizumab as an “extrema ratio

Full access

Primary Mediastinal B-Cell Lymphoma in Children and Young Adults

Christopher J. Forlenza, Amy Chadburn, and Lisa Giulino-Roth

PET alone. Emerging Biomarkers in PMBCL: Circulating Tumor DNA Given the limited predictive value of FDG-PET in PMBCL, additional biomarkers predictive of response could help to better identify patients at risk for relapse. 11 , 33 Circulating

Full access

NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas

Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler, and Jane N. Winter

– 4256 . 37 Press RD Galderisi C Yang R . A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response . Clin Cancer Res 2007 ; 13

Full access

The Role of Myeloid Growth Factors in Acute Leukemia

Martha Wadleigh and Richard M. Stone

SA DiCarlo J Groshek P . Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia . Leukemia 1991 ; 5 : 230 – 238 . 24 Frenette PS

Full access

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma

Silviya K. Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A. Elvin, Norma Palma, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, George Snipes, Veena Rajaram, Siraj M. Ali, and Isaac Melguizo-Gavilanes

. arm. However, he experienced disease relapse 4 months after completion of his CCRT, with an MRI revealing new areas of enhancement superior and medial to the left parietal lobe surgical cavity. Advanced DSC (dynamic susceptibility-weighted contrast

Full access

Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Ayman Saad, Marcos de Lima, Sarah Anand, Vijaya Raj Bhatt, Ryan Bookout, George Chen, Daniel Couriel, Antonio Di Stasi, Areej El-Jawahri, Sergio Giralt, Jonathan Gutman, Vincent Ho, Mitchell Horwitz, Joe Hsu, Mark Juckett, Mohamed Kharfan Dabaja, Alison W. Loren, MSCE, Javier Meade, Marco Mielcarek, Jonathan Moreira, Ryotaro Nakamura, Yago Nieto, Julianna Roddy, Gowri Satyanarayana, Mark Schroeder, Carlyn Rose Tan, Dimitrios Tzachanis, Jennifer L. Burns, and Lenora A. Pluchino

HCT. 11 However, disease relapse and long-term complications continue to pose a major threat to HCT survivors. Disease relapse is higher with advanced disease and with the use of nonmyeloablative conditioning regimens. Posttransplant complications are